Psoriatic arthritis: a guide for dermatology nurses.

Abstract

Psoriatic arthritis (PsA) affects people in the prime of life, causing functional impairment and diminished quality of life. Etanercept, the first FDA-approved therapy, and other immunobiologics, offer hope for favorable long-term outcomes. It is imperative that dermatology nurses learn more about the basic immunology of psoriasis and PsA and the role of immunomodulation in their treatments.

• Authors: Alice B Gottlieb
• Journal: Dermatology nursing (Dermatol Nurs) Vol. 15 Issue 2 Pg. 107-10, 113-8; quiz 119 (Apr 2003) ISSN: 1060-3441 [Print] United States
• PMID: 12751345 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antirheumatic Agents
• Cyclosporins
• Immunoglobulin G
• Immunologic Factors
• Immunosuppressive Agents
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha
• Sulfasalazine
• Infliximab
• Etanercept
• Methotrexate

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antirheumatic Agents (therapeutic use)
• Arthritis, Psoriatic (drug therapy, immunology, nursing, psychology)
• Clinical Trials, Phase III as Topic
• Cyclosporins (therapeutic use)
• Etanercept
• Humans
• Immunoglobulin G (therapeutic use)
• Immunologic Factors (therapeutic use)
• Immunosuppressive Agents (therapeutic use)
• Infliximab
• Methotrexate (therapeutic use)
• Nurse's Role
• Patient Education as Topic (methods)
• Quality of Life
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Sulfasalazine (therapeutic use)
• Treatment Outcome
• Tumor Necrosis Factor-alpha (antagonists & inhibitors, immunology)